JLinx will be based at subsidiary Janssen's Beerse campus and will be funded by J&J subsidiary Johnson & Johnson Innovation - JJDC.
Johnson & Johnson Innovation, an investment subsidiary of US-based pharmaceutical company Johnson & Johnson, launched a European incubator initiative called JLinx on Wednesday.
Johnson & Johnson and pharmaceutical research subsidiary Janssen Pharmaceuticals will partner for the program, which will be run from a dedicated facility on the Janssen campus in Beerse, Belgium.
Jlinx, which is affiliated with the recent launch of Janssen Human Microbiome Institute, will focus on microbiome research as well as other pharmaceutical and healthcare sectors. It has…
